8 February 2019 Blog Crunch time for the SPC manufacturing waiver SPC protection is an important element of the IP protection available to life sciences businesses. Providing up to five years of extra patent protection for pharmaceutical products, an SPC can make a huge difference to the profitability of a new medicine. Share this article Bookmark this page 3 min read
1 February 2019 Blog Countdown to new packaging requirements for medicines Falsified medicines are fake versions of genuine medicines that fall short of the usual high standards required. These are potentially dangerous to patients for the following reasons... Share this article Bookmark this page 2 min read
23 January 2019 Blog Four key messages about EU staff and Brexit The recent vote in the UK House of Commons to reject the EU Withdrawal Agreement may result in additional concern for EU staff and their employers in the life sciences sector. Share this article Bookmark this page 3 min read
16 January 2019 Blog Welcome changes to the ABC of Entrepreneurs’ Relief The changes to Entrepreneurs’ Relief announced in the UK Chancellor’s Autumn Budget (discussed here) rang alarm bells for some. So-called “alphabet shares” are often used to provide flexibility on the payment of dividends. Share this article Bookmark this page 2 min read
11 January 2019 Blog No-deal Brexit planning for life sciences businesses – new guidance and scenario planning Brexit uncertainty remains a fact of life for business. Next week’s Parliamentary vote on the Withdrawal Agreement is unlikely to resolve matters. For the time being, planning for no-deal is set to... Share this article Bookmark this page 5 min read
20 December 2018 Blog Patent settlement agreements – a risky business Last week’s European court rulings on a series of patent settlement agreements bring some relief to multinational pharma business Servier. The fines imposed on it by the European Commission are reduced from €330.9 to €228.32 million. Share this article Bookmark this page 4 min read
21 November 2018 Blog Warner-Lambert v Generics Part 2: infringement The Supreme Court did not have to deal with the question of infringement because they had ruled the patent invalid. But the trial judge and Court of Appeal had expressed fundamentally different views on infringement. The trial judge found the test was... Share this article Bookmark this page 4 min read
21 November 2018 Blog Supreme Court eases patent pain for the NHS, but leaves confused answers for drug companies: Warner-Lambert v Generics Part 1 Supreme Court decisions on patent law are unusual and very significant. We will provide a fuller analysis of the implications of this ruling, but for now, here is an overview... Share this article Bookmark this page 4 min read
8 October 2018 Blog Balancing transparency and confidentiality: orphan drug producer fails to prevent disclosure of clinical trial report New Jersey-based biotech company Amicus Therapeutics focuses on treatments for rare metabolic diseases. Its lead product, Galafold (migalastat), received European marketing approval for the treatment of Fabry disease in May 2016. Share this article Bookmark this page 3 min read
18 September 2018 Blog US patent infringement analysed in the English courts: Chugai v UCB A recent English patents court ruling (Chugai v UCB) has two unusual features... Share this article Bookmark this page 5 min read
2 September 2018 Blog What happens if a contracting party to an IP licence goes into an insolvency process, both from a practical and legal perspective? In the fourth article of our series on the effect of insolvency on IP licences in the life sciences sector, we look at the position of a contracting party to an IP licence which goes into an insolvency process both from a practical and legal perspective. Share this article Bookmark this page 4 min read
29 August 2018 Blog No-deal Brexit guidance for life sciences businesses The guidance issued emphasises that the Government is working hard to reach a deal with the EU, and believes that this is achievable. However, the possibility of a no-deal Brexit stays on the cards... Share this article Bookmark this page 4 min read